PROTAC compound for targeted degradation of DAPK1 protein as well as preparation method and application of PROTAC compound
By targeting the PROTAC compounds that degrade DAPK1 protein, using proteolytic targeted chimera technology, the problem of insufficient existing DAPK1 inhibitors is solved, efficient degradation of DAPK1 protein is achieved, and a new treatment plan for Alzheimer's disease is provided. .
Patent Information
- Application Number
- CN202410535326.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-04-30
AI Technical Summary
The existing DAPK1 inhibitors have insufficient activity, selectivity and drug properties, and are not effectively used to treat Alzheimer's disease. There are problems with high pricing and doubts in safety of monoclonal antibody drugs, which urgently require new treatment ideas.
Develop PROTAC compounds that target the degradation of DAPK1 protein, and use the ubiquitin-proteasome system to induce the degradation of DAPK1 protein through proteolytic targeted chimera technology to achieve the purpose of treating or preventing Alzheimer's disease. This compound ubiquitinates the target protein by bridging E3 ligase, making it recognized by the proteasome degradation system, achieving specific degradation.
It significantly degrades DAPK1 protein, is highly efficient and low toxic, can interfere with the onset of Alzheimer's disease, and provides potential methods to treat or prevent Alzheimer's disease.
Smart Images

Figure QLYQS_1 
Figure QLYQS_2 
Figure QLYQS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of preparation of drugs for neurodegenerative diseases, and in particular to a PROTAC compound for targeted degradation of DAPK1 protein, and a preparation method and application thereof. Background Art
[0002] With the aging of the population, neurodegenerative diseases have gradually become the main diseases threatening human health. Alzheimer's disease (AD) is the most common senile dementia and one of the most complex diseases. It is a chronic neurodegenerative disease caused by the degeneration of the central nervous system itself. The main neuropathological characteristics of AD are Tau protein hyperphosphorylation and Aβ deposition. However, the pathogenesis of AD is not fully understood and there is a lack of effective treatment. At present, the market demand for drugs to treat AD is highly unmet, but technological progress is not enough to compete with the disease. It belongs to the category of "disease without medicine". It is the hottest field for new drug research and development, but the risk is also extremely high. From 1993 to 2003, only five drugs such as tacrine, donepezil, rivastigmine, galantamine and memantine were approved by the FDA for the treatment of AD symptoms, and none of them could prevent or delay the progression of AD. In the nearly 20 years since then, global top pharmaceutical companies such as Pfizer, Roche, Eli Lilly, Merck and Johnson & Johnson have successively fallen on the minefield of developing anti-AD drugs. From 2021 to 2023, the FDA has successively accelerated the approval of Aduhelm (Adulumab) and Lecanemab (Lencanetumab), jointly developed by Japan's Eisai Pharmaceutical and the United States' Biogen, because they can effectively remove β-amyloid protein. However, monoclonal antibody drugs have problems such as overpricing, efficacy and safety. Therefore, it is urgent to develop small molecule drugs for the prevention and treatment of AD with new ideas.
[0003] Death-associated protein kinase 1 (DAPK1) is a calcium / calmodulin-regulated serine / threonine protein kinase. DAPK1 has multiple activities, including regulating apoptosis, autophagy, promoting the pathogenesis of AD, inhibiting tumor metastasis as a tumor suppressor gene, participating in the regulation of inflammation and immune function, mediating the body's response to viral infection, and regulating synaptic plasticity.
[0004] DAPK1 plays a central role in neuronal cell death. Studies have found that DAPK1 is expressed in large quantities in the brain and is closely related to diseases of neuronal damage such as ischemic stroke, depression, epilepsy, and AD. Many studies have shown that DAPK1 is related to the onset of AD. The two main pathological characteristics of AD are amyloid β protein (Aβ) senile plaques and tau neurofibrillary tangles. The formation of Aβ senile plaques is mainly due to the metabolism of amyloid precursor protein (APP), which causes Aβ protein to deposit outside the cell. Tau is a microtubule-associated protein that is overphosphorylated under pathological conditions to form tau aggregates. DAPK1 mainly participates in the onset of AD by over-processing APP, triggering the overphosphorylation and stabilization of tau aggregates, and is a potential target for the treatment of AD.
[0005] Currently, there are dozens of DAPK1 inhibitors reported, including TC-DAPK6 and HS-38, but due to issues with activity, selectivity, and drugability, none of them have entered clinical trials.
[0006] PROteolysis TArgeting Chimeras (PROTAC) is a technology that uses E3 ligase ubiquitination to mark target proteins (Protein of interest, POI) to specifically induce their degradation by the proteasome pathway in cells. From a chemical structure point of view, PROTAC is a hybrid bifunctional molecule that uses a linker to couple the target protein ligand (POI) and the E3 ubiquitin ligase ligand (E3). After the PROTAC molecule ubiquitinates and marks the POI and promotes the degradation of the target protein, it can dissociate from the POI and can be recycled in the cell. PROTAC is an event-driven mode of action. In theory, the dosage only needs a catalytic amount to degrade almost all target proteins in the cell. Therefore, it has a high safety and is not easy to develop drug resistance. It can also regulate some "undruggable proteins". At present, more than one hundred target proteins have been successfully degraded using PROTAC, most of which are kinase families and regulatory proteins.
[0007] DAPK1 is highly expressed in the brain tissue of 75% of AD patients; DAPK1 can increase tau protein hyperphosphorylation and Aβ secretion. DAPK1 knockout mice can reduce tau protein phosphorylation levels and Aβ production; while mice with systemic DAPK1 knockout have no obvious phenotypic defects. DAPK1 protein can mediate the pathogenesis of AD, and inhibiting or degrading the level of DAPK1 may interfere with this process and prevent the onset of AD. DAPK1 degraders have the advantages of high efficiency and low toxicity compared to inhibitors. Using PROTAC technology to reduce the content of DAPK1 protein may play a role in treating or preventing AD. Summary of the invention
[0008] In order to overcome the shortcomings of existing DAPK1 inhibitors, the present invention provides PROTAC compounds targeting the degradation of DAPK1 protein and its preparation method and application. This type of compound uses the ubiquitin-proteasome system to induce DAPK1 protein degradation through proteolysis-targeting chimeras (PROTACs) technology to achieve the effect of treating or preventing AD. One end of this type of molecule targets the E3 ligase CRBN, and the other end targets the DAPK1 protein, forming a stable ternary complex through Linker connection. The compound ubiquitinates the target protein by bridging the E3 ligase, so that the target protein is recognized by the proteasome degradation system, and then the target protein is specifically degraded.
[0009] The PROTAC compound provided by the present invention has a significant degradation effect on DAPK1 protein.
[0010] A PROTAC compound for targeted degradation of DAPK1 protein, as shown in formula Ⅰ-1 (XYZ): wherein X represents a ligand of DAPK1 protein, Z represents a ligand of E3 ligase, and Y represents a chain connecting X and Z; or X and Z are directly connected through a piperazine ring.
[0011] A PROTAC compound that targets the degradation of DAPK1 protein, wherein X is a compound shown in formula II-1, Z is a compound shown in formula II-2 or II-3, and Y is a compound shown in formula II-4.
[0012]
[0013] Each n is independently an integer between 1 and 6.
[0014] PROTAC compounds targeting the degradation of DAPK1 protein, specifically, the compounds are:
[0015] Formula 1-1, Z is Formula II-2, n = 1
[0016]
[0017] Formula 1-2, Z is Formula II-2, n=2
[0018]
[0019] Formula 1-3, Z is Formula II-2, n=3
[0020]
[0021] Formula 1-4, Z is Formula II-2, n=4
[0022]
[0023] Formula 1-5, Z is Formula II-2, n=5
[0024]
[0025] Formula 1-6, Z is Formula II-2, n=6
[0026]
[0027] Formula 1-7, Z is Formula II-3, n=2
[0028]
[0029] Formula 1-8, Z is Formula II-3, n=3
[0030]
[0031] Formula 1-9, Z is Formula II-3, n=4
[0032]
[0033] Formula 1-10, Z is Formula II-3, n=5
[0034]
[0035] Formula 1-11, Z is Formula II-3, n=6
[0036]
[0037] MG1, Z is formula II-2, X and Z are directly connected through the piperazine ring
[0038]
[0039] MG2, Z is of formula II-2, X and Z are directly connected via the piperazine ring.
[0040] The preparation method of the PROTAC compound targeting the degradation of DAPK1 protein is as follows:
[0041]
[0042]
[0043] The process flow chart of direct connection between X and Z through the piperazine ring is as follows:
[0044]
[0045] The above-mentioned PROTAC compound that targets and degrades DAPK1 protein is used to prepare a drug for treating or preventing Alzheimer's disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0046] Figure 1 This is a diagram showing the degradation of DAPK1 by the compounds obtained in the present invention, using HEK293T cell line as the experimental object;
[0047] Figure 2 The figure shows the degradation effect of compounds at different concentrations on DAPK1;
[0048] Figure 3 This is a graph showing the degradation effect of CL2 compound on DAPK1 over time;
[0049] Figure 4 The degradation of DAPK1 protein in N2a cells by CP compounds;
[0050] Figure 5 These are immunohistofluorescence images, in which: A. The hTau level in the CA3 region of the three groups of mice was detected by immunofluorescence using the HT7 antibody; B. The phosphorylation level of the Tau protein Thr231 site in the CA3 region of the hippocampus of the three groups of mice was detected by immunofluorescence using the pT231-tau antibody. DETAILED DESCRIPTION
[0051] The embodiments of the present invention will be described in further detail below. The embodiments are exemplary and intended to be used to explain the present invention, but should not be construed as limiting the present invention.
[0052] Example 1
[0053] Synthesis of 3-{[6-(1-amino-1-oxopropan-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}benzoic acid (C9S)
[0054]
[0055] Step 1: Synthesis of 3-(5-amino-4-(ethoxycarbonyl)-1H-pyrazol-1-yl)benzoic acid (1)
[0056] 2-Cyano-3-ethoxy ethyl acrylate (2447 mg, 14.5 mmol) was added to a solution of 3-hydrazinobenzoic acid hydrochloride (3000 mg, 15.9 mmol) and DIPEA (5038 μL, 28.9 mmol) in ethanol (10 mL) under stirring, and the mixture was heated under reflux for 12 h. The ethanol was removed by concentration under reduced pressure, and water (40 mL) was added for dilution, pH = 2 was adjusted with 1M hydrochloric acid, and the mixture was extracted with ethyl acetate (75 mL × 3), washed with saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (dichloromethane: methanol 50: 1). The title compound 1 was obtained as a yellow solid, 3740 mg, 13.6 mmol, with a yield of 93.7%. ESI-MS (m / z): 276.20 [M+H] + . 1 H NMR (600MHz, DMSO-d6) δ13.24(s,1H),8.04(s,1H),7.92(d,J=7.6Hz,1H),7.77(d,J=7.5Hz, 1H), 7.71 (s, 1H), 7.63 (t, J = 6.9Hz, 1H), 6.42 (s, 2H), 4.24-4.13 (m, 2H), 1.27-1.21 (m, 3H).
[0057] Step 2: Synthesis of 3-(4-hydroxy-6-mercapto-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzoic acid (2)
[0058] Compound 1 (3740 mg, 13.6 mmol) and benzoyl isothiocyanate (3995 mg, 24.5 mmol) were dissolved in anhydrous tetrahydrofuran (40 mL), refluxed under nitrogen for 16 h, and concentrated under reduced pressure to obtain the intermediate thiourea. The obtained thiourea was added dropwise to a refluxing solution of ethanol (70 mL) and sodium ethoxide (21% ethanol, 17.6 mL, 54.4 mmol), and stirred for 30 min. The mixture was concentrated under reduced pressure to dryness, diluted with water (50 mL), adjusted to pH = 2 with 1 M hydrochloric acid, filtered, washed with water, dried, and purified by silica gel column chromatography (dichloromethane: methanol 20: 1). The title compound 2 was obtained as a yellow solid, 2638 mg, 9.15 mmol, with a yield of 67.3%. ESI-MS (m / z): 289.10 [M+H] + . 1 H NMR (600MHz, DMSO-d6) δ13.29 (s, 1H), 12.25 (s, 1H), 8.14 (s, 1H), 8.07-8.00 (m, 2H), 7.80 (s, 1H), 7.66 (d, J = 8.3Hz, 1H).
[0059] Step 3: Synthesis of 3-{[6-(1-methoxy-1-oxopropan-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}benzoic acid (3)
[0060] Compound 2 (2638 mg, 9.15 mmol) and DIPEA (4.8 mL, 27.5 mmol) were dissolved in anhydrous DMF (4.0 mL). Methyl 2-bromopropionate (1681 mg, 10.1 mol) was added under stirring. The reaction was stirred at rt for 12 h, diluted with water (40 mL), adjusted to pH = 2 with 1M hydrochloric acid, extracted with ethyl acetate (75 mL × 3), washed with saturated brine (30 mL × 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure and purified by silica gel column chromatography (dichloromethane: methanol 50: 1). The title compound 3 was obtained as a yellow solid, 1387 mg, 3.70 mmol, with a yield of 40.5%. mp: 210.5~212.0℃. ESI-MS (m / z): 375.10 [M+H] + . 1 H NMR(600MHz,DMSO-d6)δ12.87(s,1H),8.60(s,1H),8.30-8.23(m,2H),7.91(d,J=7.7Hz ,1H),7.64(t,J=8.0Hz,1H),4.60(q,J=7.3Hz,1H),3.48(s,3H),1.57(d,J=7.2Hz,3H).
[0061] Step 4: Synthesis of 3-{[6-(1-amino-1-oxopropan-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}benzoic acid (C9S)
[0062] Compound 3 (750 mg, 2 mmol) was dissolved in ammonia methanol solution (7 M, 45 mL), heated to 65 ° C in a reactor for 12 h, concentrated under reduced pressure, and purified by silica gel column chromatography (dichloromethane: methanol 7.5:1). The title compound C9S was obtained as a white solid, 474 mg, 1.32 mmol, with a yield of 65.9%. mp: 228.6-230.2 ° C HRMS (ESI) m / z: [M+H] + calcdfor C 15 H 14 N5O4S:360.07665,found:360.07608. 1H NMR (600MHz, DMSO-d6) δ13.05(s,1H),8.85-8.69(m,1H),8.32(d,J=7.7Hz,1H),8.23(s,1H),7.89(d,J=7 .6Hz,1H),7.70(s,1H),7.64(t,J=7.9Hz,1H),7.25(s,1H),4.51(q,J=6.6Hz,1H),1.56(d,J=7.0Hz,3H). 13 CNMR(151MHz,DMSO-d6)δ172.84,168.30,162.87,161.70,158.62,152.39 ,138.98,136.82,129.84,127.62,124.03,121.77,105.50,45.09,19.10.
[0063] Example 2
[0064] Synthesis of 2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}ethane-1-amine trifluoroacetate (P1)
[0065]
[0066] Step 1: Synthesis of tert-butyl 2-({[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}ethyl)carbamate (O1)
[0067] To a stirred solution of 2-(2,6-dioxo-piperidin-3-yl)-4-fluoro-isoindole-1,3-dione (500 mg, 1.81 mmol) in DMSO (4 mL), add tert-butyl N-(2-aminoethyl)carbamate (377 mg, 2.35 mmol) and DIPEA (1576 μL, 9.1 mmol), stir at 145°C for 2 h, dilute with water (30 mL), extract with ethyl acetate (50 mL×3), and wash with saturated brine (20 mL×3). Dry over anhydrous sodium sulfate, concentrate under reduced pressure, and purify by silica gel column chromatography (petroleum ether: ethyl acetate 2:1). The title compound O1 was obtained as a yellow solid, 146 mg, 0.35 mmol, yield 19.4%, mp: 196.3~197.8°C. ESI-MS (m / z): 417.30 [M+H] + . 1H NMR (600MHz, DMSO-d6) δ11.05(s,1H),7.54(dd,J=8.6,7.0Hz,1H),7.10(d,J=8.6H z,1H),6.99(d,J=7.1Hz,1H),6.97(d,J=5.7Hz,1H),6.67(t,J=6.3Hz,1H),5.01(dd ,J=12.9,5.5Hz,1H),3.33(q,J=6.6Hz,2H),3.08(q,J=6.1Hz,2H),2.89-2.81(m,1H ),2.59-2.53(m,1H),2.50(dd,J=13.0,4.4Hz,1H),2.01-1.94(m,1H),1.33(s,9H).
[0068] Step 2: Synthesis of 2-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}ethane-1-amine trifluoroacetate
[0069] Compound O1 was dissolved in TFA (2 mL), heated to 50°C and stirred for 30 min, the reaction was stopped, dichloromethane (30 mL) was added and concentrated under reduced pressure to obtain the title compound P1 as a yellow oily liquid. ESI-MS (m / z): 317.25 [M+H] + . 1 H NMR(600MHz, Methanol-d4)δ7.60(t,J=7.8Hz,1H),7.16-7.09(m,2H),5.06(dd,J=11.7,4.9Hz,1H ),3.70-3.61(m,2H),3.19-3.14(m,2H),2.86-2.80(m,1H),2.76-2.67(m,2H),2.12-2.05(m,1H).
[0070] Example 3
[0071] Synthesis of 3-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}propan-1-amine trifluoroacetate (P2)
[0072]
[0073] Yellow solid compound O2 was prepared using the method described for compound O1 in Example 2. 186 mg, 0.43 mmol, yield 23.9%, mp: 96.3-97.0°C. ESI-MS (m / z): 453.25 [M+Na] + . 1H NMR(600MHz,DMSO-d6)δ11.05(s,1H),7.57-7.50(m,1H),7.05(d,J=8.6Hz,1H ),6.98(d,J=7.1Hz,1H),6.87(t,J=5.8Hz,1H),6.62(t,J=6.0Hz,1H),5.01(dd ,J=12.8,5.4Hz,1H),3.29-3.26(m,2H),2.96(q,J=6.4Hz,2H),2.89-2.80(m, 1H), 2.59-2.49 (m, 2H), 2.03-1.95 (m, 1H), 1.62 (p, J = 6.9Hz, 2H), 1.34 (s, 9H).
[0074] The yellow oily liquid compound P2 was prepared using the method described for compound P1 in Example 2. ESI-MS (m / z): 331.15 [M+H] + . 1 H NMR (600MHz, Methanol-d4) δ7.56 (t, J=7.9Hz, 1H), 7.10-7.04 (m, 2H), 5.04 (dd, J=12.9, 5.1Hz, 1H), 3.48-3. 41(m,2H),3.07-3.00(m,2H),2.89-2.79(m,1H),2.76-2.65(m,2H),2.12-2.05(m,1H),1.98(p,J=7.1Hz,2H).
[0075] Example 4
[0076] Synthesis of 4-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}butane-1-amine trifluoroacetate (P3)
[0077]
[0078] Yellow solid compound O3 was prepared using the method described for compound O1 in Example 2. 335 mg, 0.75 mmol, yield 41.6%, mp: 86.9-88.7°C. ESI-MS (m / z): 445.30 [M+H] + . 1HNMR(600MHz,DMSO-d6)δ11.07(s,1H),7.53(t,J=7.8Hz,1H),7.06(d,J=8.5Hz,1H),6.98 (d,J=6.9Hz,1H),6.81(t,J=5.6Hz,1H),6.52(t,J=6.0Hz,1H),5.01(dd,J=12.9,5.3Hz,1 H),3.26(q,J=6.6Hz,2H),2.91(q,J=6.5Hz,2H),2.88-2.82(m,1H),2.60-2.52(m,1H),2. 05-1.94(m,1H),1.50(p,J=7.4Hz,2H),1.44-1.38(m,2H),1.37-1.34(m,1H),1.33(s,9H).
[0079] The yellow oily liquid compound P3 was prepared using the method described for compound P1 in Example 2. ESI-MS (m / z): 345.25 [M+H] + . 1 H NMR (600MHz, Methanol-d4) δ7.53(t,J=7.8Hz,1H),7.04(t,J=8.7Hz,2H),5.03(dd,J=12.9,5.3Hz,1H),3.44 -3.33(m,2H),2.99-2.92(m,2H),2.90-2.79(m,1H),2.76-2.64(m,2H),2.13-2.04(m,1H),1.80-1.66(m,4H).
[0080] Example 5
[0081] Synthesis of 5-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}pentan-1-amine trifluoroacetate (P4)
[0082]
[0083] Yellow solid compound O4 was prepared using the method described for compound O1 in Example 2. 352 mg, 0.77 mmol, yield 42.4%, mp: 75.9-76.7°C. ESI-MS (m / z): 481.25 [M+Na] + . 1HNMR(600MHz,DMSO-d6)δ11.04(s,1H),7.59-7.49(m,1H),7.05(d,J=8.6Hz,1H),6.98(d,J= 7.0Hz,1H),6.73(t,J=5.7Hz,1H),6.49(d,J=6.0Hz,1H),5.01(dd,J=12.9,5.5Hz,1H),3.24( q,J=6.8Hz,2H),2.92-2.86(m,2H),2.86-2.81(m,1H),2.58-2.53(m,1H),2.50-2.47(m,1H), 2.02-1.96(m,1H),1.53(p,J=7.3Hz,2H),1.40-1.35(m,2H),1.32(s,9H),1.31-1.26(m,2H).
[0084] The yellow oily liquid compound P4 was prepared using the method described for compound P1 in Example 2. ESI-MS (m / z): 359.15 [M+H] + . 1 H NMR(600MHz,DMSO-d6)δ7.57-7.52(m,1H),7.06(d,J=8.7Hz,1H),6.99(d,J=7.0Hz, 1H), 6.50 (t, J=5.9Hz, 1H), 5.01 (dd, J=12.9, 5.5Hz, 1H), 3.26 (q, J=6.8Hz, 2H), 2.8 8-2.81(m,1H),2.61(q,J=6.6,6.1Hz,2H),2.58-2.53(m,1H),2.03-1.92(m,2H),1. 54(p,J=7.4Hz,2H), 1.43(q,J=7.5Hz,2H), 1.36-1.32(m,2H), 1.19(t,J=2.3Hz,2H).
[0085] Example 6
[0086] Synthesis of 6-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}hexane-1-amine trifluoroacetate (P5)
[0087]
[0088] Yellow solid compound O5 was prepared using the method described for compound O1 in Example 2. 293 mg, 0.62 mmol, yield 34.3%, ESI-MS (m / z): 473.50 [M+H] + . 1H NMR (600MHz, DMSO-d6) δ11.08(s,1H),7.54(t,J=7.9Hz,1H),7.05(d,J=8.7Hz,1H),6.98(d, J=7.1Hz,1H),6.75(d,J=5.8Hz,1H),6.50(t,J=5.8Hz,1H),5.01(dd,J=12.9,5.3Hz,1H),3. 24(q,J=6.8Hz,2H),2.86(q,J=6.5Hz,3H),2.57-2.53(m,1H),2.49(d,J=3.3Hz,1H),2.02-1 .95(m,1H),1.52(p,J=7.6,7.1Hz,2H),1.32(s,11H),1.31-1.26(m,2H),1.26-1.21(m,2H).
[0089] The yellow oily liquid compound P5 was prepared using the method described for compound P1 in Example 2. ESI-MS (m / z): 373.30 [M+H] + . 1 H NMR(600MHz, Methanol-d4)δ7.53(t,J=7.8Hz,1H),7.06-6.98(m,2H),5.03(dd,J=12.8,5.3Hz,1H),3.36-3.31(m,2H) ,2.90(t,J=7.7Hz,2H),2.85-2.80(m,1H),2.76-2.70(m,2H),2.12-2.05(m,1H),1.72-1.61(m,4H),1.51-1.41(m,4H).
[0090] Example 7
[0091] Synthesis of 7-{[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}heptane-1-amine trifluoroacetate (P6)
[0092]
[0093] Yellow solid compound O6 was prepared using the method described for compound O1 in Example 2. 276 mg, 0.57 mmol, yield 31.3%, ESI-MS (m / z): 487.30 [M+H] + ,509.25[M+Na] + . 1H NMR (600MHz, DMSO-d6) δ11.07(s,1H),7.54(t,J=7.8Hz,1H),7.05(d,J=8.6Hz,1 H),6.98(d,J=7.0Hz,1H),6.73(t,J=5.6Hz,1H),6.49(t,J=5.9Hz,1H),5.01(dd, J=12.8,5.4Hz,1H),3.25(q,J=6.8Hz,2H),2.87-2.80(m,4H),2.59-2.53(m,1H) ,2.02-1.96(m,1H),1.52(p,J=7.5,7.0Hz,2H),1.32(s,13H),1.29-1.23(m,4H).
[0094] The yellow oily liquid compound P6 was prepared using the method described for compound P1 in Example 2. ESI-MS (m / z): 387.25 [M+H] + . 1 H NMR (600MHz, Methanol-d4) δ7.52(t,J=7.8Hz,1H),7.01(d,J=7.8Hz,2H),5.03(dd,J=12.9,5.3Hz,1H),3.33-3.29(m,2H),2.91 -2.86(m,2H),2.85-2.79(m,1H),2.75-2.67(m,2H),2.11-2.05(m,1H),1.68-1.60(m,4H),1.47-1.42(m,2H),1.42-1.37(m,4H).
[0095] Example 8
[0096] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}ethyl)benzamide (CP1)
[0097]
[0098] HBTU (159 mg, 0.42 mmol) was added to a DMSO (2 mL) solution of C9S (571 mg, 0.42 mmol), P1 (181 mg, 0.42 mmol) and triethylamine (292 μL, 2.1 mmol) under stirring, and the mixture was reacted overnight at rt, diluted with water (20 mL), extracted with ethyl acetate (75 mL×3), washed with brine (10 mL×2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and purified by silica gel column chromatography (dichloromethane: methanol 15:1). The title compound CP1 was obtained as a yellow solid, 35 mg, 0.05 mmol, with a yield of 12.8%, mp: 223.8~224.4°C. HPLC: 95.932%. HRMS (ESI) m / z: [M+H] + Calculate for C 30 H 28 N9O7S:658.18324,found:658.18335. 1 H NMR (600MHz, DMSO-d6) δ12.79(s,1H),11.07(s,1H),8.92(t,J=5.2Hz,1H),8.61(s,1H),8.26(d,J=3.8Hz, 2H),7.80(d,J=7.7Hz,1H),7.71(s,1H),7.62(t,J=8.1Hz,1H),7.54(t,J=7.8Hz,1H),7.26(s,1H),7.23(d ,J=8.5Hz,1H),6.99(d,J=7.0Hz,1H),6.84(t,J=5.6Hz,1H),5.01(dd,J=13.0,5.4Hz,1H),4.49(q,J=7.2H z,1H),3.54-3.43(m,4H),2.88-2.79(m,1H),2.58-2.52(m,1H),2.01-1.93(m,1H),1.54(d,J=7.0Hz,3H). 13 C NMR (151MHz, DMSO-d6) δ173.34,172.81,170.63,169.26,167.84,166.85,162.85,161.29,152.20,146.88,138.95,136.94,136. 76,135.89,132.79,129.98,125.71,124.01,120.37,117.71,111.13,109.88,105.48,49.07,45.17,41.78,31.51,22.69,19.02.
[0099] Example 9
[0100] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({3-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}propyl)benzamide (CP2)
[0101]
[0102] The title compound CP2 was prepared using the method described for compound CP1 in Example 8 as a yellow solid, 46 mg, 0.07 mmol, yield 16.1%, mp: 209.9-210.0°C. HPLC: 97.911%. HRMS (ESI) m / z: [M+H] + Calculate for C 31 H 30 N9O7S:672.19889,found:672.19910. 1 H NMR (600MHz, DMSO-d6) δ11.07(s,1H),8.79(d,J=5.8Hz,1H),8.63(s,1H),8.29(d,J=8.1Hz,1H),8.10(s,1H),7. 77(d,J=7.4Hz,2H),7.59(t,J=7.9Hz,1H),7.54(t,J=7.9Hz,1H),7.13(s,1H),7.08(d,J=8.6Hz,1H),6.98(d,J=6 .9Hz,1H),6.74(t,J=6.0Hz,1H),5.01(dd,J=12.9,5.4Hz,1H),4.44(q,J=7.2Hz,1H),3.37-3.34(m,4H),2.89-2. 78(m,1H),2.59-2.51(m,1H),2.50-2.47(m,1H),2.02-1.95(m,1H),1.79(p,J=6.7Hz,2H),1.47(d,J=7.0Hz,3H). 13C NMR(151MHz,DMSO-d6)δ173.37,172.82,170.66,169.38,167.85,166.51,161.19,157.96,152.15,146.80,138.92,136.92,136.77, 136.10,132.80,129.93,125.72,123.92,120.38,117.66,110.95,109.75,105.47,49.09,45.23,37.43,31.53,29.15,22.71,19.02.
[0103] Example 10
[0104] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}butyl)benzamide (CP3)
[0105]
[0106] The title compound CP3 was prepared using the method described for compound CP1 in Example 8 as a yellow solid, 67 mg, 0.10 mmol, yield 23.3%, mp: 206.9-207.5°C. HPLC: 99.951%. HRMS (ESI) m / z: [M+H] + Calculate for C 32 H 32 N9O7S:686.2145,found:686.2137;[M+Na] + Calculate for C 32 H 31 N9NaO7S:708.1965,found:708.1982. 1H NMR (600MHz, DMSO-d6) δ12.77(s,1H),11.06(s,1H),8.71(t,J=5.6Hz,1H),8.62(s,1H),8.25(d,J=2.0Hz,1H),8. 23(d,J=8.0Hz,1H),7.81(d,J=7.7Hz,1H),7.70(s,1H),7.61(t,J=8.2Hz,1H),7.52(t,J=7.8Hz,1H),7.26(s,1H) ,7.08(d,J=8.5Hz,1H),6.97(d,J=6.9Hz,1H),6.55(t,J=5.9Hz,1H),5.01(dd,J=13.2,5.4Hz,1H),4.51(q,J=7.2 Hz,1H),3.31(s,4H),2.89-2.79(m,1H),2.58-2.52(m,1H),2.03-1.91(m,2H),1.59(s,4H),1.53(d,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ173.38,172.82,170.66,169.47,167.84,166.27,161.16,157.98,152.14,146.93,138.91,136.91,136.78,136 .16,132.72,129.92,125.69,123.88,120.39,117.72,110.93,109.57,105.45,49.08,45.24,42.09,31.51,26.96,26.79,22.69,19.07.
[0107] Embodiment 11
[0108] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({5-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}pentyl)benzamide (CP4)
[0109]
[0110] The title compound CP4 was prepared using the method described for compound CP1 in Example 8 as a yellow solid, 40 mg, 0.06 mmol, yield 13.6%, mp: 187.9-188.5°C. HPLC: 99.764%. HRMS (ESI) m / z: [M+H] + Calculate for C33 H 34 N9O7S:700.23019,found:700.23016. 1 H NMR(600MHz,DMSO-d6)δ11.08(s,1H),8.76-8.70(m,1H),8.64(s,1H),8.25(d,J=8.1Hz,1H),8.15(s,1H),7.7 7(d,J=5.9Hz,2H),7.59(t,J=7.9Hz,1H),7.53(t,J=7.8Hz,1H),7.20(s,1H),7.06(d,J=8.6Hz,1H),6.97(d,J= 6.9Hz,1H),6.52(t,J=5.8Hz,1H),5.01(dd,J=12.9,5.5Hz,1H),4.56-4.43(m,1H),3.29-3.23(m,5H),2.89-2 .80(m,1H),2.59-2.51(m,1H),2.02-1.94(m,1H),1.61-1.53(m,4H),1.49(d,J=7.1Hz,3H),1.40-1.35(m,2H). 13 C NMR(151MHz,DMSO-d6)δ173.36,172.80,170.65,169.49,167.84,166.20,161.13,157.92,152.12,146.95,138.90,136.91,136.79,136.20 ,132.70,129.89,125.69,123.82,120.38,117.69,110.92,109.55,10 5.45,49.08,45.27,42.34,31.52,29.28,28.98,24.35,22.69,19.12.
[0111] Example 12
[0112] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({6-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}hexyl)benzamide (CP5)
[0113]
[0114] The title compound CP5 was prepared using the method described for compound CP1 in Example 8 as a yellow solid, 202 mg, 0.28 mmol, yield 67.4%, mp: 164.9-165.9°C. HPLC: 98.260%. HRMS (ESI) m / z: [M+H] + Calculate for C 34 H 36 N9O7S:714.24584,found:714.24506. 1 H NMR (600MHz, DMSO-d6) δ11.08(s,1H),8.68(d,J=6.7Hz,1H),8.63(s,1H),8.25(s,1H),8.22(d,J=8.0Hz, 1H),7.81(d,J=7.7Hz,1H),7.71(s,1H),7.61(t,J=7.9Hz,1H),7.52(t,J=7.9Hz,1H),7.28(s,1H),7.04( d,J=8.6Hz,1H),6.97(d,J=7.0Hz,1H),6.51(s,1H),5.01(dd,J=13.2,5.6Hz,1H),4.57-4.46(m,1H),3.2 8-3.22(m,5H),2.89-2.80(m,1H),2.59-2.52(m,1H),2.03-1.95(m,1H),1.57-1.48(m,7H),1.34(s,4H). 13 C NMR(151MHz,DMSO-d6)δ173.25,172.70,170.55,169.43,167.76,166.10,161.05,157.83,152.05,146.89,138.83,136.82,136.70,136.17,13 2.65,129.81,125.61,123.75,120.33,117.58,110.83,109.51,105.37 ,49.03,45.22,42.29,31.46,29.44,29.13,26.69,26.56,22.64,19.06.
[0115] Embodiment 13
[0116] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({7-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino}heptyl)benzamide (CP6)
[0117]
[0118] The title compound CP6 was prepared using the method described for compound CP1 in Example 8 as a yellow solid, 124 mg, 0.17 mmol, yield 40.5%, mp: 158.7-159.1°C. HPLC: 98.465%. HRMS (ESI) m / z: [M+H] + Calculate for C 35 H 38 N9O7S:728.26149,found:728.26123. 1 H NMR (600MHz, DMSO-d6) δ12.78(s,1H),11.07(s,1H),8.67(d,J=6.7Hz,1H),8.62(s,1H),8.25(s,1H),8.21(d,J=8 .0Hz,1H),7.80(d,J=7.7Hz,1H),7.71(s,1H),7.61(t,J=8.0Hz,1H),7.52(t,J=7.8Hz,1H),7.28(s,1H),7.04(d,J =8.7Hz,1H),6.97(d,J=7.1Hz,1H),6.50(s,1H),5.01(dd,J=13.1,5.3Hz,1H),4.51(q,J=7.2Hz,1H),3.29-3.19(m ,5H),2.89-2.80(m,1H),2.60-2.51(m,1H),2.02-1.95(m,1H),1.57-1.52(m,5H),1.51-1.47(m,2H),1.31(s,6H). 13 C NMR(151MHz,DMSO-d6)δ173.26,172.70,170.55,169.42,167.76,166.08 ,161.04,157.83,152.05,146.89,138.83,136.82,136.70,136.17,132.6 4,129.81,125.60,123.73,120.32,117.58,110.82,109.48,105.37,49.0 3,45.22,42.32,31.46,29.45,29.14,28.97,26.93,26.78,22.63,19.07.
[0119] Embodiment 14
[0120] Synthesis of 3-{[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl]amino}propane-1-amine trifluoroacetate (L2)
[0121]
[0122] Step 1: Synthesis of tert-butyl 3-({[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl]amino}propyl)carbamate (K2)
[0123] To a stirred solution of lenalidomide (771 mg, 2.97 mmol) in NMP (4 mL), add tert-butyl N-(3-bromopropyl)carbamate (848 mg, 3.56 mmol) and DIPEA (2590 μL, 14.9 mmol), stir at 110 ° C for 12 h, dilute with water (30 mL), extract with ethyl acetate (75 mL × 3), and wash with saturated brine (20 mL × 5). Dry over anhydrous sodium sulfate, concentrate under reduced pressure, and purify by silica gel column chromatography (dichloromethane: methanol 200: 3). Obtain yellow solid compound K2, 176 mg, 0.42 mmol, yield 14.2%, ESI-MS (m / z): 417.25 [M+H] + ,439.20[M+Na] + . 1 H NMR (600MHz, DMSO-d6) δ10.98(s,1H),7.24(t,J=7.7Hz,1H),6.89(d,J=7.3Hz,1H),6.86(d,J=5. 9Hz,1H),6.70(d,J=8.0Hz,1H),5.54(t,J=5.5Hz,1H),5.08(dd,J=13.4,4.9Hz,1H),4.19(d,J=1 7.0Hz,1H),4.09(d,J=17.1Hz,1H),3.09(q,J=6.6Hz,2H),2.98(q,J=6.6Hz,2H),2.94-2.84(m,1 H),2.62-2.55(m,1H),2.32-2.21(m,1H),2.03-1.97(m,1H),1.65(p,J=7.2Hz,2H),1.34(s,9H).
[0124] Step 2: Synthesis of 3-{[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl]amino}propane-1-amine trifluoroacetate (L2)
[0125] K2 was dissolved in dichloromethane (6 mL), ice-bathed for 30 min, trifluoroacetic acid (3 mL) was added dropwise, the ice-bath was removed, stirred at rt for 2 h, and concentrated under reduced pressure to obtain a yellow oily liquid compound L2, ESI-MS (m / z): 317.25 [M+H] + . 1 H NMR (600MHz, Methanol-d4) δ7.33(t,J=7.8Hz,1H),7.09(d,J=7.4Hz,1H),6.86(d,J=8.0Hz,1H),5.14(dd,J=13.4,5.0Hz,1H),4.26(q,J=16.8 Hz,2H),3.39-3.31(m,2H),3.09-3.01(m,2H),2.95-2.84(m,1H),2.81 -2.72(m,1H),2.49-2.38(m,1H),2.20-2.11(m,1H),2.04-1.94(m,2H).
[0126] Embodiment 15
[0127] Synthesis of 4-{[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl]amino}butane-1-amine trifluoroacetate (L3)
[0128]
[0129] The yellow solid compound K3.76 mg, 0.18 mmol, was prepared using the method described for compound K2 in Example 14. The yield was 5.9%. ESI-MS (m / z): 431.30 [M+H] + ,453.25[M+Na] + . 1 H NMR (400MHz, DMSO-d6) δ11.03(s,1H),7.28(t,J=7.7Hz,1H),6.93(d,J=7.4Hz,1H),6.83(t,J=5.6H z,1H),6.75(d,J=8.1Hz,1H),5.60(t,J=5.6Hz,1H),5.12(dd,J=13.3,5.1Hz,1H),4.23(d,J=17.1H z,1H),4.12(d,J=17.1Hz,1H),3.12(q,J=6.4Hz,2H),3.00-2.93(m,2H),2.932.86(m,1H),2.672.5 7(m,1H),2.36-2.22(m,1H),2.09-1.98(m,1H),1.61-1.52(m,2H),1.51-1.42(m,2H),1.37(s,9H).
[0130] The yellow oily liquid compound L3 was prepared using the method described for compound L2 in Example 14. ESI-MS (m / z): 331.15 [M+H] + . 1 H NMR (600MHz, Methanol-d4) δ7.31(t,J=7.9Hz,1H),7.07(d,J=7.4Hz,1H),6.83(d,J=8.0Hz,1H),5.14(dd,J=13.4,5.2Hz,1H),4.31-4.18(m, 2H),3.28-3.26(m,2H),2.94(t,J=7.3Hz,2H),2.92-2.87(m,1H),2.81 -2.73(m,1H),2.48-2.39(m,1H),2.19-2.11(m,1H),1.81-1.68(m,4H).
[0131] Example 16
[0132] Synthesis of 5-{[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl]amino}pentan-1-amine trifluoroacetate (L4)
[0133]
[0134] Yellow solid compound K4 was prepared using the method described for compound K2 in Example 14. 345 mg, 0.78 mmol, yield 26.1%, ESI-MS (m / z): 467.30 [M+Na] + . 1 H NMR (600MHz, DMSO-d6) δ10.98(s,1H),7.24(t,J=7.6Hz,1H),6.88(d,J=7.5Hz,1H),6.75(t,J=5.9Hz ,1H),6.70(d,J=7.9Hz,1H),5.53(t,J=5.2Hz,1H),5.08(dd,J=13.4,5.0Hz,1H),4.19(d,J=17.0Hz, 1H),4.09(d,J=17.0Hz,1H),3.06(q,J=6.4Hz,2H),2.88(q,J=6.3Hz,3H),2.63-2.55(m,1H),2.32-2 .21(m,1H),2.04-1.97(m,1H),1.58-1.47(m,2H),1.40-1.35(m,2H),1.33(s,9H),1.31-1.27(m,2H).
[0135] The yellow oily liquid compound L4 was prepared using the method described for compound L2 in Example 14. ESI-MS (m / z): 345.30 [M+H] + . 1 H NMR (600MHz, Methanol-d4) δ7.30(t,J=7.7Hz,1H),7.05(d,J=7.4Hz,1H),6.80(d,J=8.0Hz,1H),5.12(dd,J=13.6,5.0Hz,1H),4.25(q,J=16.8Hz,2H),3.24 -3.19(m,2H),2.91(t,J=7.6Hz,2H),2.88-2.83(m,1H),2.79-2.72(m,1H),2. 47-2.37(m,1H),2.17-2.11(m,1H),1.72-1.64(m,4H),1.49(p,J=7.7Hz,2H).
[0136] Embodiment 17
[0137] Synthesis of 6-{[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl]amino}hexane-1-amine trifluoroacetate (L5)
[0138]
[0139] The yellow solid compound K5 was prepared using the method described for compound K2 in Example 14. 378 mg, 0.82 mmol, yield 27.7%, ESI-MS (m / z): 459.40 [M+H] + . 1 H NMR (600MHz, DMSO-d6) δ10.98(s,1H),7.24(t,J=7.8Hz,1H),6.88(d,J=7.3Hz,1H),6.75( d,J=5.9Hz,1H),6.70(d,J=8.0Hz,1H),5.53(t,J=5.6Hz,1H),5.08(dd,J=13.4,5.0Hz,1H) ,4.19(d,J=17.1Hz,1H),4.09(d,J=17.1Hz,1H),3.06(q,J=6.5Hz,2H),2.93-2.84(m,3H), 2.64-2.55(m,1H),2.33-2.22(m,1H),2.04-1.95(m,1H),1.59-1.49(m,2H),1.33(s,15H).
[0140] The yellow oily liquid compound L5 was prepared using the method described for compound L2 in Example 14. ESI-MS (m / z): 359.30 [M+H] + . 1 H NMR (600MHz, Methanol-d4) δ7.30(t,J=7.9Hz,1H),7.05(d,J=7.5Hz,1H),6.80(d,J=8.0Hz,1H),5.13(dd,J=13.2,4.9Hz,1H),4.25(q,J=16.8 Hz,2H),3.25-3.19(m,2H),2.92-2.85(m,3H),2.80-2.76(m,1H),2.49 -2.41(m,1H),2.18-2.13(m,1H),1.71-1.61(m,4H),1.51-1.39(m,4H).
[0141] Embodiment 18
[0142] Synthesis of 7-{[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl]amino}heptane-1-amine trifluoroacetate (L6)
[0143]
[0144] Yellow solid compound K6 was prepared using the method described for compound K2 in Example 14. 428 mg, 0.91 mmol, yield 30.5%, ESI-MS (m / z): 473.35 [M+H] + . 1 H NMR (600MHz, DMSO-d6) δ10.99(s,1H),7.24(t,J=7.7Hz,1H),6.88(d,J=7.4Hz,1H),6.74(t,J=5.6Hz,1H), 6.69(d,J=8.1Hz,1H),5.54(d,J=5.5Hz,1H),5.08(dd,J=13.3,5.0Hz,1H),4.18(d,J=17.1Hz,1H),4.08(d ,J=17.1Hz,1H),3.06(q,J=6.5Hz,2H),2.93-2.88(m,1H),2.85(q,J=6.5Hz,2H),2.61-2.55(m,1H),2.30- 2.21(m,1H),2.02-1.96(m,1H),1.53(p,J=7.1Hz,2H),1.32(s,13H),1.28-1.23(m,2H),1.23-1.18(m,2H).
[0145] The yellow oily liquid compound L6 was prepared using the method described for compound L2 in Example 14. ESI-MS (m / z): 373.35 [M+H] + . 1 H NMR (600MHz, Methanol-d4) δ7.30(t,J=7.8Hz,1H),7.06(d,J=7.5Hz,1H),6.81(d,J=8.1Hz,1H),5.13(dd,J=13.4,5.0Hz,1H),4.31-4.19(m,2H),3.2 5-3.19(m,2H),2.91-2.85(m,3H),2.80-2.75(m,1H),2.50-2.38(m,1H),2 .19-2.12(m,1H),1.71-1.59(m,4H),1.47-1.42(m,2H),1.41-1.36(m,4H).
[0146] Embodiment 19
[0147] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({3-[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl]amino}propyl)benzamide (CL2)
[0148]
[0149] The title compound CL2 was prepared as a white solid using the method described for compound CP1 in Example 8, 23 mg, 0.03 mmol, yield 8.33%, mp: 158.7-159.1°C. HPLC: 95.715%. HRMS (ESI) m / z: [M+H] + Calculate for C 31 H 32 N9O6S:658.21963,found:658.21930. 1H NMR (600MHz, DMSO-d6) δ12.79(s,1H),10.99(s,1H),8.76(d,J=5.6Hz,1H),8.61(s,1H),8.24(d,J=14.4Hz,2H),7.81(d,J=7.7Hz,1H ),7.72(s,1H),7.62(t,J=7.9Hz,1H),7.25(dd,J=15.6,8.0Hz,2H),6.90(d,J=7.4Hz,1H),6.74(d,J=8.1Hz,1H),5.62(t,J=5.5Hz,1H ),5.07(dd,J=13.4,5.1Hz,1H),4.52-4.48(m,1H),4.19(d,J=17.0Hz,1H),4.10(d,J=17.1Hz,1H),3.38(q,J=6.6Hz,2H),3.18(q,J= 6.6Hz,2H),2.93-2.83(m,1H),2.60-2.54(m,1H),2.31-2.21(m,1H),2.02-1.93(m,1H),1.83(p,J=6.8Hz,2H),1.53(d,J=7.1Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ173.45,172.79,171.79,169.44,166.43,161.12,157.89,152.13,144.15,138.91,136.94,136.16,132.62, 129.95,129.78,127.14,125.73,123.93,120.41,112.41,110.66,105.46,52.06,46.23,45.26,40.99,31.77,28.91,23.33,19.06.
[0150] Embodiment 20
[0151] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({4-[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl]amino}butyl)benzamide (CL3)
[0152]
[0153] The title compound CL3 was prepared as a white solid using the method described for compound CP1 in Example 8, 62 mg, 0.09 mmol, yield 22.0%, mp: 206.4-207.1°C. HPLC: 95.747%. HRMS (ESI) m / z: [M+H] + Calculate for C 32 H 34 N9O6S:672.23528,found:672.23462. 1 H NMR (600MHz, DMSO-d6) δ10.99(s,1H),8.71(t,J=5.2Hz,1H),8.62(s,1H),8.26(s,1H),8.23(d,J=7.8Hz,1H),7.81(d,J=7.7Hz,1 H),7.71(s,1H),7.61(t,J=7.8Hz,1H),7.28(s,1H),7.23(t,J=7.8Hz,1H),6.88(d,J=7.3Hz,1H),6.72(d,J=8.0Hz,1H),5.62-5.5 6(m,1H),5.07(dd,J=13.6,5.0Hz,1H),4.50(q,J=6.9Hz,1H),4.18(d,J=17.1Hz,1H),4.08(d,J=17.1Hz,1H),3.31-3.26(m,2H), 3.17-3.10(m,2H),2.922.83(m,1H),2.61-2.53(m,1H),2.30-2.20(m,1H),2.02-1.95(m,1H),1.61(s,4H),1.53(d,J=6.9Hz,3H). 13 C NMR(151MHz,DMSO-d6)δ173.46,172.82,171.80,169.48,166.25,161.11,157.91,152.12,144.26,138.90,136.92,136.20,132.58,129 .92,129.75,127.03,125.70,123.89,120.40,112.31,110.51,105.45,52.04,46.28,45.26,42.96,31.77,27.25,26.50,23.35,19.06.
[0154] Embodiment 21
[0155] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({5-[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl]amino}pentyl)benzamide (CL4)
[0156]
[0157] The title compound CL4 was prepared using the method described for compound CP1 in Example 8 as a white solid, 49 mg, 0.07 mmol, yield 17.0%, mp: 249.6-250.3°C. HPLC: 96.664%. HRMS (ESI) m / z: [M+H] + Calculate for C 33 H 36 N9O6S:686.25093,found:686.25018. 1 H NMR (600MHz, DMSO-d6) δ10.99(s,1H),8.70(d,J=5.7Hz,1H),8.62(s,1H),8.25(s,1H),8.22(d,J=8.2Hz,1H),7.81(d,J=7.7Hz,1H),7.71(s ,1H),7.61(t,J=7.9Hz,1H),7.28(s,1H),7.24(t,J=7.7Hz,1H),6.88(d,J=7.4Hz,1H),6.71(d,J=8.0Hz,1H),5.55(t,J=5.4Hz,1H),5.07(d d,J=13.4,5.1Hz,1H),4.51(q,J=7.1Hz,1H),4.18(d,J=17.1Hz,1H),4.08(d,J=17.0Hz,1H),3.27(q,J=7.0Hz,2H),3.09(q,J=6.5Hz,2H),2 .93-2.82(m,1H),2.62-2.54(m,1H),2.29-2.19(m,1H),2.03-1.93(m,1H),1.62-1.55(m,4H),1.54(d,J=7.0Hz,3H),1.39(p,J=7.7Hz,2H). 13C NMR(151MHz,DMSO-d6)δ173.47,172.82,171.80,169.49,166.23,161.09,157.89,152.11,144.31,138.89,136.91,136.23,132.56,129.91 ,129.76,126.99,125.71,123.86,120.40,112.27,110.48,105.45,5 2.05,46.29,45.27,43.24,31.77,29.44,28.81,24.67,23.34,19.09.
[0158] Embodiment 22
[0159] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({6-[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl]amino}hexyl)benzamide (CL5)
[0160]
[0161] The title compound CL5 was prepared using the method described for compound CP1 in Example 8 as a white solid, 27 mg, 0.04 mmol, yield 9.19%, mp: 259.4-259.7°C. HPLC: 98.693%. HRMS (ESI) m / z: [M+H] + Calculate for C 34 H 38 N9O6S:700.26658,found:700.26599. 1H NMR (600MHz, DMSO-d6) δ12.79(s,1H),10.99(s,1H),8.69(d,J=5.6Hz,1H),8.64-8.60(m,1H),8.26(d,J=1.9Hz,1H),8.22(d,J=8.0Hz,1H), 7.81(d,J=7.7Hz,1H),7.72(s,1H),7.61(t,J=8.1Hz,1H),7.29(s,1H),7.23(t,J=7.8Hz,1H),6.87(d,J=7.3Hz,1H),6.69(d,J=8.0Hz,1H),5 .54(t,J=5.3Hz,1H),5.07(dd,J=13.5,5.0Hz,1H),4.51(q,J=6.8Hz,1H),4.18(d,J=17.1Hz,1H),4.08(d,J=17.1Hz,1H),3.26(q,J=6.6Hz,2 H),3.07(q,J=6.6Hz,2H),2.93-2.84(m,1H),2.61-2.54(m,1H),2.30- 2.21(m,1H),2.03-1.96(m,1H),1.60-1.48(m,7H),1.41-1.29(m,4H). 13 C NMR(151MHz,DMSO-d6)δ173.45,172.74,171.81,169.45,166.15,161.10,157.87,152.12,144.31,138.89,136.94,136.26,132.58,129.92,12 9.75,127.00,125.71,123.86,120.41,112.24,110.43,105.44,52.02, 46.27,45.28,43.22,31.77,29.59,29.04,26.93,26.91,23.36,19.13.
[0162] Embodiment 23
[0163] Synthesis of 3-{6-[(1-amino-1-oxopropane-2-yl)thio]-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-1-yl}-N-({7-[2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-4-yl]amino}heptyl)benzamide (CL6)
[0164]
[0165] The title compound CL6 was prepared using the method described for compound CP1 in Example 8 as a white solid, 35 mg, 0.05 mmol, yield 11.7%, mp: 266.5-267.0°C. HPLC: 97.859%. HRMS (ESI) m / z: [M+H] + Calculate for C 35 H 40 N9O6S:714.28223,found:714.28131. 1 H NMR (400MHz, DMSO-d6) δ12.82(s,1H),11.03(s,1H),8.89-8.54(m,2H),8.43-8.13(m,2H),7.92-7.58( m,3H),7.41-7.17(m,2H),6.99-6.86(m,1H),6.73(d,J=8.0Hz,1H),5.69-5.47(m,1H),5.24-5.02(m,1 H),4.56(q,J=15.2,12.6Hz,1H),4.31-4.03(m,2H),3.29-3.23(m,2H),3.16-3.06(m,2H),2.95-2.85( m,1H),2.71-2.59(m,1H),2.37-2.22(m,1H),2.10-1.96(m,1H),1.68-1.46(m,7H),1.44-1.26(m,6H). 13 C NMR(151MHz,DMSO-d6)δ173.46,172.79,171.81,169.47,166.16,161.10 ,157.89,152.12,144.31,138.89,136.92,136.24,132.56,129.92,129.7 4,126.99,125.69,123.85,120.40,112.24,110.43,105.44,52.04,46.2 8,45.28,43.27,31.77,29.56,29.21,29.06,27.16,27.06,23.35,19.11.
[0166] Embodiment 24
[0167] MG1 and MG2 are prepared by the following process flow chart:
[0168]
[0169] Example 25: Degradation of DAPK1 protein in HEK293T cells by the compound
[0170] Total protein was extracted from HEK293T cells using RIPA lysis buffer containing protease and phosphatase inhibitors. The protein concentration was then determined using BCA protein assay reagent. Protein samples (15-30 μg) were separated by SDS / PAGE and transferred to a PVDF membrane by semi-dry transfer. Nonspecific sites were then blocked with 5% milk-TBST or 5% BSA-TBST at room temperature for 1 hour, and the primary antibody was added to the sample and then incubated overnight at 4°C. The membrane was washed three times with TBST to remove additional primary antibodies, and then HRP-conjugated secondary antibodies were added, and the samples were incubated at room temperature for 1 hour. All membranes were then coated with ECL chemiluminescent enzyme-linked substrate and imaged using an imaging system. In order to determine whether the target compound has a degradation effect on DAPK1 protein, the HEK293T cell line was used as the experimental subject to test the degradation of the compound on DAPK1. The degradation results are shown in the figure. Figure 1 As shown in Figure 3, after 24 h of action at a concentration of 5 μM, CL2 and CP1 were able to more significantly degrade DAPK1 protein.
[0171] CL2 and CP1 with better activity were selected to test the degradation effect of the compounds on DAPK1 with increasing concentrations when the action time was 24 hours. The results are as follows Figure 2 As shown. CL2 and CP1 significantly downregulated the DAPK1 protein level after 24 hours at a concentration of 5 μM, and the degradation effect increased with the increase in concentration. When the concentration reached 10 μM, the DAPK1 protein was almost completely degraded. Then we selected CL2 and continued to detect the degradation effect of different action times on the DAPK1 protein when the concentration was 10 μM. The results are shown in Figure 3 As shown in the figure. CL2 at a concentration of 10 μM can significantly reduce the level of DAPK1 protein after 6 hours of action, and reaches maximum degradation at 12 hours. After 12 hours, the degradation effect no longer changes with the extension of the action time. This may be due to the compensatory synthesis of new DAPK1 protein in the cell after the decrease of DAPK1 protein level.
[0172] Example 26: Degradation of DAPK1 protein in N2a cells by compounds
[0173] Total protein was extracted from N2a cells using RIPA lysis buffer containing protease and phosphatase inhibitors. Protein concentration was then determined using BCA protein assay reagent. Protein samples (15-30 μg) were separated by SDS / PAGE and transferred to PVDF membranes by semi-dry transfer. Nonspecific sites were then blocked with 5% milk-TBST or 5% BSA-TBST for 1 hour at room temperature, and primary antibodies were added to the samples and then incubated overnight at 4°C. The membranes were washed three times with TBST to remove additional primary antibodies, and then HRP-conjugated secondary antibodies were added, and the samples were incubated for 1 hour at room temperature. All membranes were then coated with ECL chemiluminescent enzyme-linked substrate and imaged using an imaging system, see Figure 4 shown.
[0174] Example 27 Effect of CP1 on tau protein in the CA3 region of the mouse hippocampus
[0175] The 2-month-old male mice used in the experiment were purchased from Shanghai Wu Animal Experimental Center and maintained under a 12-h light cycle in the standard specific pathogen-free area of the Experimental Animal Center of Fujian Medical University, with free access to food and water.
[0176] Stereotaxic brain surgery: AAV-CMV-Tau(P301L)-EGFP-WPRE, AAV-CMV-EGFP-WPRE was purchased from Wuhan Shumi Brain Science Technology Co., Ltd. Mice were anesthetized by isoflurane inhalation and fixed in a stereotaxic instrument. After iodine disinfection, the skin was incised along the anterior-posterior axis to expose the skull. Injection holes were made at 2.2 mm posterior, 2.7 mm right, and 2.3 mm below the bregma using a hand-held drill. Tau-P301L virus or vector virus was injected into the CA3 region at a rate of 125 nL / min through a microinjection pump. The needle remained in place for 5 minutes before being withdrawn. The mice were then sutured and placed on a heating pad for recovery.
[0177] Immunohistofluorescence: 5 μm coronal sections were prepared from paraffin-embedded specimens of mouse brain tissue and subjected to immunohistofluorescence staining. After deparaffinization, rehydration, and antigen retrieval, the sections were blocked with goat serum for 1 hour at room temperature for nonspecific sites. The primary antibody was added to the sections and incubated overnight at 4°C. After washing three times with PBST, Alexa Fluor 488 or 546-conjugated secondary antibodies were added to the sections under light-protected conditions and incubated for one hour at room temperature. After washing three times with PBST, staining with Hoechst33342 for 10 minutes, washing three times with PBST, and all samples were sealed with anti-fade agents and then observed and photographed under a fluorescence microscope.
[0178] To investigate the effect of CP1 on Tau pathology in the hippocampus of mice, we detected the levels of total hTau protein and phosphorylation sites of Tau protein associated with Alzheimer's disease. First, we used HT7 antibody to detect the total hTau protein level in the brain tissues of the three groups of mice by immunofluorescence technique. The results are shown in Figure 5 It was found that compared with the AAV-eGFP group, the HT7 fluorescence signal in the AAV-P301L group was significantly increased; compared with the AAV-P301L group, the HT7 fluorescence signal in the AAV-P301L+CP1 group was significantly decreased. Figure 5 (A) As shown. At the same time, we used pT231-tau antibody to detect the phosphorylation level of Tau protein in the brain tissues of the three groups of mice. The results showed that compared with the AAV-eGFP group, the pT231-tau fluorescence signal in the AAV-P301L group was significantly increased; compared with the AAV-P301L group, the pT231-tau fluorescence signal in the AAV-P301L+CP1 group was significantly reduced. The above results show that CP1 treatment can reduce the abnormal aggregation and phosphorylation of Tau protein in the mouse hippocampus.
Claims
1. A PROTAC compound targeting the degradation of DAPK1 protein, characterized in that: As shown in Formula I-1: XYZ formula Ⅰ-1; Wherein, X represents a ligand of DAPK1 protein, Z represents a ligand of E3 ligase, and Y represents a chain connecting X and Z; or X and Z are directly connected via a piperazine ring.
2. The PROTAC compound targeting the degradation of DAPK1 protein according to claim 1, characterized in that The X is a compound represented by formula II-1, the Z is a compound represented by formula II-2 or II-3, and the Y is a compound represented by formula II-4. Each n is independently an integer between 1 and 6.
3. The PROTAC compound targeting the degradation of DAPK1 protein according to claim 2, characterized in that The compound is: Formula 1-1, Z is Formula II-2, n = 1 Formula 1-2, Z is Formula II-2, n=2 Formula 1-3, Z is Formula II-2, n=3 Formula 1-4, Z is Formula II-2, n=4 Formula 1-5, Z is Formula II-2, n=5 Formula 1-6, Z is Formula II-2, n=6 Formula 1-7, Z is Formula II-3, n=2 Formula 1-8, Z is Formula II-3, n=3 Formula 1-9, Z is Formula II-3, n=4 Formula 1-10, Z is Formula II-3, n=5 Formula 1-11, Z is Formula II-3, n=6 MG1, Z is formula II-2, X and Z are directly connected through the piperazine ring MG2, Z is of formula II-2, X and Z are directly connected via the piperazine ring.
4. The method for preparing a PROTAC compound targeting the degradation of DAPK1 protein according to any one of claims 1 to 3, characterized in that: The process is as follows:
5. The method for preparing a PROTAC compound targeting the degradation of DAPK1 protein according to claim 3, characterized in that: The process flow chart of direct connection between X and Z through the piperazine ring is as follows:
6. Use of the PROTAC compound targeting the degradation of DAPK1 protein according to claim 1 for preparing a drug for treating or preventing neurodegenerative diseases.
7. The use according to claim 6, characterized in that The neurodegenerative disease is Alzheimer's disease, Parkinson's disease or Huntington's disease.
Citation Information
Patent Citations
Preparation method of PTOTAC BTK degradation agent
CN115461343A
PROTAC compound for targeted degradation of PTP1B as well as preparation method and application of PROTAC compound
CN115677815A
HyT compound for targeted degradation of DAPK1 protein and application of HyT compound in neurodegenerative diseases
CN118666847A
Protac antibody conjugates and methods of use
WO2017201449A1
Cited By
HyT compound for targeted degradation of DAPK1 protein and application of HyT compound in neurodegenerative diseases
CN118666847A
Hyt compound targeting degradation of dapk1 protein and application thereof in neurodegenerative diseases
CN118666847B
Dicyanoisophorone derivative, preparation method thereof and application of dicyanoisophorone derivative as near-infrared fluorescent probe for detecting COX-2
CN121574086A
A dicyanoketone derivative, a preparation method thereof and application of the dicyanoketone derivative as a near-infrared fluorescent probe for detecting COX-2
CN121574086B
